Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT03263572
What this trial is testing

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaBCR-ABL1 Fusion Protein Expression+5 more
M.D. Anderson Cancer Center 90
Large-scale testing (Phase 3)Study completedNCT00471497
What this trial is testing

Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Who this might be right for
Myelogenous Leukemia, Chronic
Novartis Pharmaceuticals 846
Large-scale testing (Phase 3)Study completedNCT00006343
What this trial is testing

STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Who this might be right for
Leukemia
Novartis
Large-scale testing (Phase 3)Study completedNCT02326311
What this trial is testing

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

Who this might be right for
Leukemia, Chronic Myeloid
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia 229
Large-scale testing (Phase 3)UnknownNCT00002771
What this trial is testing

Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Who this might be right for
Leukemia
German CML Study Group 750
Early research (Phase 1)Study completedNCT00114257
What this trial is testing

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaMyelodysplastic Syndromes+1 more
National Cancer Institute (NCI) 36
Not applicableActive Not RecruitingNCT06665412
What this trial is testing

Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML

Who this might be right for
Chronic Phase Ph+ Chronic Myeloid Leukemia
Il-Yang Pharm. Co., Ltd. 169
Testing effectiveness (Phase 2)WithdrawnNCT02923986
What this trial is testing

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

Who this might be right for
Chronic Myelogenous Leukemia, Ph1-PositiveAcute Myeloid LeukemiaMyelodysplastic Syndrome
Bio-Path Holdings, Inc.
Early research (Phase 1)Study completedNCT00588991
What this trial is testing

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Who this might be right for
Adult Acute Megakaryoblastic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic Leukemia+20 more
National Cancer Institute (NCI) 12
Post-approval studies (Phase 4)Ended earlyNCT02228382
What this trial is testing

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

Who this might be right for
Previously Treated PH + CML
Pfizer 163
Post-approval studies (Phase 4)Study completedNCT06427811
What this trial is testing

Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation

Who this might be right for
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Novartis Pharmaceuticals 85
Large-scale testing (Phase 3)Temporarily pausedNCT01755325
What this trial is testing

Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+

Who this might be right for
Chronic Myelogenous Leukemia
Junmin Li 680
Testing effectiveness (Phase 2)Active Not RecruitingNCT01424982
What this trial is testing

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaAdult Acute Lymphoblastic Leukemia in Complete Remission+4 more
M.D. Anderson Cancer Center 88
Early research (Phase 1)Study completedNCT01077544
What this trial is testing

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Chronic Myeloid LeukemiaAcute Lymphoblastic Leukemia
Novartis Pharmaceuticals 15
Large-scale testing (Phase 3)Ended earlyNCT02115386
What this trial is testing

Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib

Who this might be right for
Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
Novartis Pharmaceuticals 7
Post-approval studies (Phase 4)Study completedNCT01735955
What this trial is testing

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Who this might be right for
Chronic Myelogenous Leukemia (CML)Metastatic Gastrointestinal Stromal Tumors (GIST)Acute Lymphoblastic Leukemia (ALL)+1 more
Novartis Pharmaceuticals 57
Early research (Phase 1)Study completedNCT01456676
What this trial is testing

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

Who this might be right for
Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Novartis Pharmaceuticals 11
Not applicableEnded earlyNCT01073436
What this trial is testing

Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha

Who this might be right for
Chronic Myeloid Leukemia
University of Michigan Rogel Cancer Center 7
Large-scale testing (Phase 3)Study completedNCT01275196
What this trial is testing

Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients

Who this might be right for
Chronic Myeloid Leukemia
Novartis Pharmaceuticals 267
Testing effectiveness (Phase 2)Study completedNCT01784068
What this trial is testing

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

Who this might be right for
Chronic Myelogenous Leukemia
Novartis Pharmaceuticals 215
Next Page